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CELLULAR immunity to encephalito-
genicfactor (EF)inpatientswithmalignant
neoplasia has been demonstrated on a
number ofoccasions, using boththemacro-
phage electrophoretic mobility (MEM) test
(Field and Caspary, 1970; Goldstone et al.,
1973; Pritchard et al., 1972) and the mac-
rophage migration inhibition (MMI) test
(Shelton et al., 1975; Light et al., 1975;
Flavell and Potter, 1978). The demonstra-
tion by Caspary and Field (1971) that
lymphocytes from cancer patients also
respond to an acid extract of tumour
tissues in the MEM test led to the proposal
that the lymphocyte response to EF in
malignant disease represented a response
to neoantigens on the tumour cell surface
immunologically cross-reactive with EF.
This acid-extractable protein from malig-
nant tissues has been called cancer basic
protein (CaBP). In support of this hypo-
thesis, McDermott et al. (1974) and Coates
and Carnegie (1975) have presented evi-
dence for the sharing of antigenic deter-
minants between EF and CaBP. Moreover,
Dickinson et al. (1972) have demonstrated
that the antigenic activity of CaBP in
tumour cells grown in vitro is associated
exclusively with the plasma membrane.
Studies in hamsters bearing trans-
plantedSV40-inducedtumourshaveshown
that a spleen-cell response to EF develops
in these animals 10-21 days after tumour
implantation (Shelton et al., 1975; Flavell
et al., 1978). If the spleen-cell response to
EF in these tumour-bearing animals rep-
resents a cell-mediated immune response
directed against neoantigen(s) on the
tumour cell surface, then immunization
with EF or CaBP might be expected to
induce a degree of transplantation immu-
nity to theSV40tumour. Thepresentstudy
was designed to investigate the effects
of immunization with EF or CaBP
on the growth of SV40 tumours in ham-
sters.
A transplantable SV40-induced tumour
of hamsters was used. It was originally in-
duced by the inoculation of SV40 virus
into a newborn hamster, and maintained
for the past 5 years in this laboratory by
s.c. passage at 2-3-week intervals. Single-
cell suspensions were prepared by physical
disruption of tumour tissue followed by
washing x 3 in Medium 199 by centrifuga-
tion at 800 g. Tumour-cell viabilities were
estimated by trypan-blue exclusion, and
the cells were adjusted to the desired con-
centration in Medium 199 containing 10%
foetal calf serum. Bovine EF and human
CaBP from carcinoma of the ovary were
prepared according to the method of J. P.
Dickinson (personal communication). An
aqueous extract ofa hamster SV40 tumour
was prepared by homogenizing the tumour
tissue in 4 vols of ice-cold glass-distilled
water followed by centrifugation of the
homogenate at 30,000 g for 30 min. The
supernatant was collected, and designated
as the aqueous SV40 extract. The proteinD. J. FLAVELL AND C. W. POTTER
content of the supernatant was 1-5 mg/ml
as determined by the Biuret method.
Groups of hamsters were immunized
twice with either 50 pg of EF or CaBP in
Freund's complete adjuvant (FCA) into
alternate footpads; the first immunization
preceding the second by 8 days. A group
ofhamsters were immunized in anidentical
manner with 0 05 ml of the aqueous SV40
tumour extract in FCA, and control ani-
mals were immunized with FCA contain-
ing only an equivalent volume of saline.
Twenty-one days after the first immuniza-
tion, each group ofanimals were challenged
s.c. by injection into the left flank ofeither
103, 105 or 106 viable SV40 tumour cells.
Table I shows the incidence of tumours in
TABLE I.-Incidence of tumour takes in
hamsters immunized with bovine EF,
human CaBP, an aqueous extract of a
hamster SV40 tumour or Freund's com-
plete adjuvant (FCA) only (controls) and
challenged s.c. with 103, 105 or 106 SV40
tumour cells.
Tumour
Immunized cell
with inoculum
EF 103
105
106
CaBP 103
105
106
SV40 103
extract 105
106
FCA 103
(controls) 105
106
Incidence of tumours*
No. days after inoculation of
tumour cells
6 8 10 14 16
0/10 0/9 2/8 4/8 4/8
6/10 8/10 9/10 9/10 9/10
2/10 4/10 8/10 10/10
0/10 0/10
6/9 9/9
7/9 7/9
2/8
9/9
7/9
0/10 0/10 0/10
0/10 2/10 3/10
6/9 6/8 7/8
0/10 0/10 3/8
3/8 6/8 7/8
9/9 9/9 9/9
5/9 5/9
9/9 9/9
8/8
0/9 2/9
5/10 6/10
7/7
4/8
7/8
9/9
4/8
7/8
* No. tumour takes/No. of animals receiving
tumour cells.
each group of animals observed over a
period of 16 days. Immunization with EF
or CaBP did not confer any protection
against tumour growth, at any of the
tumour-cell inocula employed. However,
animals immunized with the aqueous
SV40 tumour extract, which received 103
or 105 SV40 tumour cells, showed a signi-
ficant reduction in the rate of tumour
growth (P<0 05) compared to that seen
in control animals.
In a second set ofexperiments, the Winn
adoptive-transfer assay (Winn, 1961) was
employed to determine the effects of EF-,
CaBP- or SV40-tumour-immune spleen
cells on the growth of SV40 tumour cells
in vivo. Spleen cells from hamsters im-
munized with EF or CaBP as described
above and spleen cells from hamsters
bearing SV40 tumours for a period of 21
days, were mixed with SV40 tumour cells
in a ratio of 10:1 (106 spleen cells: 105
tumour cells/ml) or 100:1 (107 spleen
cells: 105 tumour cells/ml) in Medium 199.
Control spleen cells were obtained from
animals immunized with FCA containing
only an equivalent volume of saline.
Groups of 10 hamsters were inoculated
s.c. with 0.1 ml ofa given cell mixture into
the left flank, and the incidence oftumours
in these animals over a 16-day period is
shown in Table II. Spleen cells from
tumour-bearing animals, when mixed with
tumour cells at a ratio of 100:1, signifi-
cantly reduced thegrowth rate oftumours
when compared with control animals.
Thus, this assay system was capable of
detecting transplantation-type immunity
to the SV40 tumour. In contrast, cells
from animals immunized with EF or
CaBP gave no protection against SV40-
tumour growth, at spleen cell:tumour
cell ratios of 10:1 or 100:1. These
results are interpreted as showing that EF
or CaBP sensitization does not give pro-
tection against SV40-tumour growth, and
is evidence against the hypothesis that the
delayed hypersensitivity response to EF
seen in malignant neoplasia is an inmmu-
nological reaction directed against a neo-
antigen(s) on the tumour-cell surface.
However, it has been demonstrated that
embryonic antigens expressed on the sur-
face of certain experimental animal tu-
mour cells are not always capable of in-
ducing transplantation-type immunity
(Chism et al., 1976; Basombrio and Prehn,
1972). Both these effects may be related
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TABLE II.-Incidence of tumour takes in hamsters inoculated s.c. with spleen cells from
animals immunized with EF, CaBP or FCA only (controls) or spleen cellsfromt tumour-
bearing animals admixed with SV40 tumour cells at a ratio of 10:1 or 100:1
Incidence of tumourst
Spleen cell* Spleen cells No. days after inoculation of tumour cells
tumour cell from animals ,
ratio immunized with 6 8 10 14 16
10:1 EF 8/10 9/10 10/10 10/10 10/10
CaBP 8/10 9/10 9/9 9/9 9/9
SV40-Tumour
Bearers 5/10 8/10 10/10 10/10 9/9
FCA (Controls) 6/10 8/10 10/10 10/10 10/10
100:1 EF 8/10 9/10 10/10 10/10 10/10
CaBP 7/10 9/10 10/10 10/10 9/9
SV40-Tumour
Bearers 2/10 5/10 5/10 5/10 7/10
FCA (Controls) 6/10 9/10 10/10 10/10 10/10
* Spleen cells and tumour cells mixed and injected together s.c.
t No. tumour takes/No. animals receiving tumour cells.
to the density of antigenic determinants
on the tumour-cell surface, to a rapid
turnover of antigen or to sequestration of
antigen, which might allow the tumour to
escape from immunological cytotoxic re-
actions directedagainsttheantigen. Whilst
immunization with EF or CaBP does not
appear to induce transplantation-type
immunity to the SV40 tumour in the assay
systems employed in the present study,
this should not be taken as conclusive
evidence that the delayed hypersensitivity
response to EF seen in animals bearing
SV40 tumours is not due to an immuno-
logical reaction directed against neoanti-
gen(s) on the tumour-cell surface.
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